Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Check Again: The Problem With Reproducibility

This article was originally published in Start Up

Executive Summary

Promising academic results prove elusive when the experiments are run again, threatening reputations and wasting industry resources. Everyone is scrambling for a fix, but is the problem as bad as it seems, and do we really need a top-down solution?

You may also be interested in...

Woodcock Pushes Standardization to Speed Rx Development, But Will Uniformity Cripple Innovation?

CDER’s director lays out a standardized roadmap to biomedical innovation starting with basic research; others worry an industrialized process is what got industry into the productivity decline in the first place.

Spurred By Necessity, Industry And Academia Are Learning To Share

After a prior era of failed collaborations, industry and academia are increasingly joining forces in ways that better accommodate each others’ capabilities and goals – and, they hope, will create more value and ultimately greater improvements to human health.

KRS Pioneers Optogenetics Tools


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts